Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.59
OTCPK:TEVJF's Cash to Debt is ranked lower than
73% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. OTCPK:TEVJF: 0.59 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:TEVJF' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.33 Max: N/A
Current: 0.59
Equity to Asset 0.55
OTCPK:TEVJF's Equity to Asset is ranked lower than
63% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OTCPK:TEVJF: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:TEVJF' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.50 Max: 0.6
Current: 0.55
0.39
0.6
Interest Coverage 7.91
OTCPK:TEVJF's Interest Coverage is ranked lower than
68% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. OTCPK:TEVJF: 7.91 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TEVJF' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.22 Max: N/A
Current: 7.91
F-Score: 6
Z-Score: 2.13
M-Score: -2.88
WACC vs ROIC
5.53%
3.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.10
OTCPK:TEVJF's Operating margin (%) is ranked higher than
62% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. OTCPK:TEVJF: 12.10 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:TEVJF' s Operating margin (%) Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 12.1
8.12
25.46
Net-margin (%) 9.13
OTCPK:TEVJF's Net-margin (%) is ranked higher than
61% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. OTCPK:TEVJF: 9.13 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:TEVJF' s Net-margin (%) Range Over the Past 10 Years
Min: 5.73  Med: 12.03 Max: 20.75
Current: 9.13
5.73
20.75
ROE (%) 6.60
OTCPK:TEVJF's ROE (%) is ranked lower than
52% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. OTCPK:TEVJF: 6.60 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:TEVJF' s ROE (%) Range Over the Past 10 Years
Min: 4.23  Med: 10.00 Max: 16.18
Current: 6.6
4.23
16.18
ROA (%) 3.48
OTCPK:TEVJF's ROA (%) is ranked lower than
52% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. OTCPK:TEVJF: 3.48 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:TEVJF' s ROA (%) Range Over the Past 10 Years
Min: 2.26  Med: 4.98 Max: 9.34
Current: 3.48
2.26
9.34
ROC (Joel Greenblatt) (%) 33.29
OTCPK:TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. OTCPK:TEVJF: 33.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:TEVJF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.41  Med: 33.40 Max: 49.79
Current: 33.29
16.41
49.79
Revenue Growth (3Y)(%) -0.80
OTCPK:TEVJF's Revenue Growth (3Y)(%) is ranked lower than
69% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OTCPK:TEVJF: -0.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:TEVJF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 15.60 Max: 23.4
Current: -0.8
-0.8
23.4
EBITDA Growth (3Y)(%) 6.60
OTCPK:TEVJF's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. OTCPK:TEVJF: 6.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:TEVJF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 14.80 Max: 47.3
Current: 6.6
-10.5
47.3
EPS Growth (3Y)(%) -6.80
OTCPK:TEVJF's EPS Growth (3Y)(%) is ranked lower than
69% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. OTCPK:TEVJF: -6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:TEVJF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.5  Med: 15.40 Max: 69.6
Current: -6.8
-25.5
69.6
» OTCPK:TEVJF's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF855.004.287 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVA.USA,
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").

Ratios

vs
industry
vs
history
P/E(ttm) 26.91
TEVJF's P/E(ttm) is ranked higher than
51% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. TEVJF: 26.91 )
Ranked among companies with meaningful P/E(ttm) only.
TEVJF' s P/E(ttm) Range Over the Past 10 Years
Min: 10.53  Med: 20.68 Max: 1072.29
Current: 26.91
10.53
1072.29
PE(NRI) 26.91
TEVJF's PE(NRI) is ranked higher than
51% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. TEVJF: 26.91 )
Ranked among companies with meaningful PE(NRI) only.
TEVJF' s PE(NRI) Range Over the Past 10 Years
Min: 10.53  Med: 20.67 Max: 938.25
Current: 26.91
10.53
938.25
Price/Owner Earnings (ttm) 15.11
TEVJF's Price/Owner Earnings (ttm) is ranked higher than
81% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. TEVJF: 15.11 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TEVJF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.93  Med: 18.92 Max: 67.1
Current: 15.11
8.93
67.1
P/B 1.76
TEVJF's P/B is ranked higher than
68% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. TEVJF: 1.76 )
Ranked among companies with meaningful P/B only.
TEVJF' s P/B Range Over the Past 10 Years
Min: 1.36  Med: 2.27 Max: 4.81
Current: 1.76
1.36
4.81
P/S 2.32
TEVJF's P/S is ranked higher than
56% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. TEVJF: 2.32 )
Ranked among companies with meaningful P/S only.
TEVJF' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 3.00 Max: 5.83
Current: 2.32
1.58
5.83
PFCF 9.41
TEVJF's PFCF is ranked higher than
83% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. TEVJF: 9.41 )
Ranked among companies with meaningful PFCF only.
TEVJF' s PFCF Range Over the Past 10 Years
Min: 8.46  Med: 18.21 Max: 97.63
Current: 9.41
8.46
97.63
POCF 8.13
TEVJF's POCF is ranked higher than
82% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. TEVJF: 8.13 )
Ranked among companies with meaningful POCF only.
TEVJF' s POCF Range Over the Past 10 Years
Min: 6.58  Med: 11.91 Max: 23.41
Current: 8.13
6.58
23.41
EV-to-EBIT 23.43
TEVJF's EV-to-EBIT is ranked lower than
58% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. TEVJF: 23.43 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 20.60 Max: 991
Current: 23.43
11.4
991
EV-to-EBITDA 15.19
TEVJF's EV-to-EBITDA is ranked higher than
56% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. TEVJF: 15.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVJF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9  Med: 16.75 Max: 290.6
Current: 15.19
9
290.6
PEG 10.76
TEVJF's PEG is ranked lower than
89% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. TEVJF: 10.76 )
Ranked among companies with meaningful PEG only.
TEVJF' s PEG Range Over the Past 10 Years
Min: 0.34  Med: 1.12 Max: 119.22
Current: 10.76
0.34
119.22
Shiller P/E 20.37
TEVJF's Shiller P/E is ranked higher than
82% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. TEVJF: 20.37 )
Ranked among companies with meaningful Shiller P/E only.
TEVJF' s Shiller P/E Range Over the Past 10 Years
Min: 18.81  Med: 30.02 Max: 75.06
Current: 20.37
18.81
75.06
Current Ratio 1.32
TEVJF's Current Ratio is ranked lower than
78% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVJF: 1.32 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 1.32
0.92
2.95
Quick Ratio 1.01
TEVJF's Quick Ratio is ranked lower than
76% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. TEVJF: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.08 Max: 2.19
Current: 1.01
0.63
2.19
Days Inventory 182.49
TEVJF's Days Inventory is ranked lower than
78% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. TEVJF: 182.49 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.40 Max: 208.14
Current: 182.49
131.65
208.14
Days Sales Outstanding 97.21
TEVJF's Days Sales Outstanding is ranked lower than
65% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. TEVJF: 97.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 97.21
95.91
153.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.92
TEVJF's Price/Projected FCF is ranked higher than
87% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. TEVJF: 0.92 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVJF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.51 Max: 29.19
Current: 0.92
0.65
29.19
Price/DCF (Earnings Based) 2.08
TEVJF's Price/DCF (Earnings Based) is ranked lower than
73% of the 70 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. TEVJF: 2.08 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.77
TEVJF's Price/Median PS Value is ranked higher than
80% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. TEVJF: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVJF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.12 Max: 1.98
Current: 0.77
0.54
1.98
Earnings Yield (Greenblatt) (%) 4.30
TEVJF's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TEVJF: 4.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVJF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 4.85 Max: 8.8
Current: 4.3
0.1
8.8
Forward Rate of Return (Yacktman) (%) -1.57
TEVJF's Forward Rate of Return (Yacktman) (%) is ranked lower than
67% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. TEVJF: -1.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVJF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -4.6  Med: 21.85 Max: 43.7
Current: -1.57
-4.6
43.7

More Statistics

Revenue (TTM) (Mil) $19,480
EPS (TTM) $ 1.92
Beta-0.50
Short Percentage of Float0.00%
52-Week Range $57.25 - 69.24
Shares Outstanding (Mil)914.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22,519 24,771 25,583
EPS ($) 5.29 6.01 6.46
EPS without NRI ($) 5.29 6.01 6.46
EPS Growth Rate
(3Y to 5Y Estimate)
7.40%
» More Articles for OTCPK:TEVJF

Headlines

Articles On GuruFocus.com
Stocks Near 52-Week Lows May 26 2016 
John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Time To Buy Allergan Apr 06 2016 
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Mar 31 2016 
Fight Market Malaise with These Four Sector Strategies Mar 30 2016 
Bernard Horn Comments on Teva Pharmaceutical Mar 21 2016 
Polaris Global Value Fund Annual Letter 2015 Mar 21 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Andreas Halvorsen Raises Stake in Teva Pharmaceutical Mar 09 2016 

More From Other Websites
Allergan: Standing Out From the Pack May 27 2016
Stocks Near 5a-Week Lows May 26 2016
5 Health Care Stocks Whose Charts Tell You to Wait to Buy May 26 2016
Short Sellers Take Mixed Stance on Major Pharma May 25 2016
Is This the Perfect Time to Buy Teva? May 24 2016
General Motors Company (GM): Are Hedge Funds Right Fleeing This Stock? May 23 2016
Mexico FDI rises to record high in first quarter May 23 2016
Allergan CEO says company is 'weeks away' from closing Teva deal May 23 2016
Allergan CEO says company is "weeks away" from closing Teva deal May 23 2016
J&J is Worth as Much as Gilead, Biogen, Mylan, Celgene and Teva Combined. It's Time to Sell. May 20 2016
Specialty Pharma Stocks are Cheap…But Only Some are Worth Buying May 20 2016
[$$] Generics Stocks Deserve More Love May 19 2016
Will Drugmaker Endo Become a Penny Stock by the End of the Year? May 16 2016
This Company Benefits From U.S. Treasury Rules May 16 2016
Sell These 5 Stocks Now Before It's Too Late May 13 2016
Allergan's Results Were Exactly the Soft Catalyst We Wanted May 11 2016
Major Pharma Short Interest Continues to Recede May 11 2016
Israeli Stocks Are Dragged Down by Teva Pharmaceutical May 10 2016
Teva's Future Value Contingent on Pipeline Growth May 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)